Healing & Recovery · Research Use Only
ARA-290
Also known as: Cibinetide, Erythropoietin-derived peptide
ARA-290 is an 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO). It is studied in preclinical models for its interaction with the innate repair receptor and for neuroprotective and anti-inflammatory signaling pathways.
View ARA-290 product →What is ARA-290?
ARA-290, also known as cibinetide, is a synthetic peptide of eleven amino acids whose sequence is drawn from the tissue-protective domain of erythropoietin (EPO). Unlike full-length EPO, this fragment does not carry the region associated with red-blood-cell production.
This design allows researchers to study the tissue-protective signaling of EPO in isolation from its role in erythropoiesis.
It is reputedly known within neuropathy, recovery, and regenerative-wellness communities for its purported ability to support nerve health and dampen inflammation while sparing red-blood-cell effects.
Purported Benefits & Research Focus
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin that engages the innate repair receptor, and researchers are investigating its purported neuroprotective and tissue-protective properties. It is popularly associated in biohacking circles with nerve health and small-fiber neuropathy support.
The peptide is anecdotally reported for its reputed anti-inflammatory action and its potential to aid recovery without stimulating the blood-cell production linked to conventional EPO. Preclinical and early clinical studies have explored ARA-290 in neuropathic and inflammatory research models.
Discussion also centers on tissue protection and metabolic and healing support, but these represent areas of active or preclinical investigation and community interest, not outcomes established in humans.
How ARA-290 is studied
In laboratory and animal models, ARA-290 has been examined for its interaction with the innate repair receptor, a complex thought to combine the EPO receptor with the beta-common receptor. Through this pathway, researchers have studied mechanisms related to neuroprotection and the modulation of inflammatory responses in injured tissue.
Preclinical work has explored effects on nerve-fiber and immune-cell behavior in controlled settings. These findings characterize receptor-level and cellular mechanisms and are not equivalent to human outcomes.
Handling, reconstitution & storage
ARA-290 arrives as a lyophilized powder that should be stored at -20°C, sealed and shielded from light. It is reconstituted with bacteriostatic or sterile water for research use; reconstituted material is generally kept at 4°C for near-term handling or split into aliquots at -80°C for longer storage. A certificate of analysis with HPLC purity results is provided with each lot.
Not sure which solvent to use? See the reconstitution guide for a per-peptide breakdown of bacteriostatic vs acetic acid water.
Frequently asked questions
How is ARA-290 related to erythropoietin?
ARA-290 is an 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin, without the region tied to red-blood-cell production.
What receptor is ARA-290 studied against?
In preclinical research it is examined for its interaction with the innate repair receptor, an EPO-receptor / beta-common-receptor complex.
References
Related research peptides
Shop research-grade ARA-290, HPLC-tested with a COA on every batch.
View ARA-290 →All information here is provided for laboratory and research reference only. Products are sold strictly for in-vitro research and development and are not for human or veterinary use.